Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

NCT04500431 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Targeting CD269 chimeric antigen receptor engineered T cells

Sponsor

Shanghai Tongji Hospital, Tongji University School of Medicine